Blue Jet Healthcare Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/66islqoa52kban9ectibb8ry.pdf

Key Takeaways


Revenue Deferral: The Red Sea Effect

VK Singh: "So, as that being a pure-play CDMO, we are in contact with a lot of innovator companies. And for whatever reason you attribute it to, China plus one or whatever you call it they are tailwinds for Indian companies."

Pharma Intermediates: The Cardiovascular Ramp


Margins: A Surprising Upside

Shiven Arora: "I think both the product categories are for the innovators. And these are specialized products and as we gain more experience in these categories and the specific products our efficiencies are improving with time. So the aspiration would be around the same margin levels and be consistent in terms of suppliers."

Capacity Build-Out: Saturation Forces a Greenfield

VK Singh: "So, the greenfield will be required because now existing capacities are saturated. There's no further debottlenecking or addition of blocks in the existing capacities possible."

Contrast Media: The Waiting Game

Shiven Arora: "There's no specific delay, actually. I think this is a complex molecule and has gone through series of use test trials and validations and stability studies. Things like this typically can have a certain amount of delay, but overall outlook when it comes to this advanced intermediate and the necessity from a sourcing point of view by the customer is there."
VK Singh: "I don't think anybody else has got a continuous process. So I think our costs will be pretty much in control. We'll be one of the industry leaders as far as cost is concerned and there'll be a lot of headroom to fight."

Sweeteners & Other Segments


Guidance & Commitments

CommitmentSpecificsTimeline
Cardiovascular intermediate rampIncreased offtake from new 120 KL capacity; orders in hand, validation passedQ3 FY25 onward
MRI contrast media intermediateAdditional 70–80 KL capacity commercial; validation batches shippedQ3 FY25 (Sep/Oct)
Small volume plantCommissioning for proof of concept, regulatory filings, small GMP quantitiesQ1 FY26
Unit III backward integration blockContrast media backward integration capacity commissionedQ1 FY26
Committed capex spend₹200 cr to be spent12–18 months
Capacity addition40–50% more capacity added12–18 months
Greenfield siteOne or two blocks ready to augment capacity1–1.5 years
Employee cost trendContinued headcount additions for new capacities and corporate functionsNext 12 months
Freight cost normalizationOcean freight rates expected to resolve~1 quarter

Key Metrics

MetricQ1 FY25
Revenue₹163 cr, -11% QoQ
EBITDA margin27.2% as on Q1 FY25
EBITDA margin (quarterly)27%, vs 29% in Q4 FY24
PAT margin23%, marginally higher than Q4 FY24
ROCE22% annualised basis
Fixed asset turnoverover 3x
Cash and treasury investmentsover ₹380 cr, debt-free
Contrast media revenue change-42% QoQ
Pharmaceutical Intermediates revenue growth60% growth in Q1 FY25
Gross margin changeimproved by 1% QoQ, helped by raw material cost easing and product mix
Depreciation₹3.5 cr, vs ₹7.7 cr in Q4 FY24, due to change to straight-line method
Inventory days204 days, up from 136 days in Q4 FY24, predominantly due to goods in transit
Capex capitalised in Q1₹90 cr
Committed capex pipeline₹200 cr to be spent over 12–18 months
Capacity utilisation70%–75%
Manpower expense changeup 14% QoQ
Goods in transit not recognised as revenuemore than at least 50% of quarterly turnover, analyst computed ~₹80 cr
Ocean freight transit time60–65 days, up from 35–40 days previously